This study included a relatively large Chinese population that was not administered lipid-lowering treatment before admission to evaluate for the first time the relationships among PCSK9, noninvasive liver fibrosis score, and cardiovascular events, providing novel information in the field of cardiovascular and liver disease. The gene discussed is PCSK9; the disease is Hepatic fibrosis.